文献速递银屑病与炎症性皮肤病

银屑病及银屑病关节炎系统治疗与主要心血管不良事件风险关联的回顾性队列研究

Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2025-03-26

结果显示生物制剂较光疗与新发和复发MACE风险降低相关,非生物系统性治疗仅在既往有MACE史患者中较光疗降低MACE风险。

要点

  • 生物制剂较光疗与新发MACE风险降低相关(aHR 0.454,95%CI 0.359-0.574)。
  • 生物制剂较光疗与复发MACE风险降低相关(aHR 0.343,95%CI 0.245-0.479)。
  • 非生物系统性治疗仅在既往MACE史患者中较光疗降低MACE风险(aHR 0.789,95%CI 0.658-0.946)。

核心结论

  • 研究支持在中重度银屑病或银屑病关节炎患者中使用生物制剂,尤其适用于MACE病史者这类治疗选择有限的人群。

研究设计与样本

  • 共纳入183,212例患者,产生259,475个治疗疗程。
  • 主要结局为MACE(急性心肌梗死、卒中、心脏骤停、不稳定型心绞痛或心力衰竭),采用多变量时间依赖Cox回归模型进行风险分析。

主要发现

  • 生物制剂较光疗与新发MACE风险降低相关(调整后风险比0.454;95%CI 0.359-0.574)。
  • 生物制剂较光疗与复发MACE风险降低相关(调整后风险比0.343;95%CI 0.245-0.479)。
  • 非生物系统性治疗仅在既往有MACE史的患者中较光疗显示MACE风险降低(调整后风险比0.789;95%CI 0.658-0.946)。

临床怎么用

  • 对中重度银屑病或银屑病关节炎患者,可考虑优先选用生物制剂以降低新发及复发MACE风险。
  • 对既往有MACE史且治疗选择有限的患者,生物制剂的使用获得研究支持。

局限性

  • 观察性设计限制因果推断,并可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on managing psoriasis and psoriatic arthritis (PsA) in survivors of major adverse cardiovascular events (MACEs). OBJECTIVE: To investigate the risk of recurrent and new-onset MACEs associated with systemic therapies for psoriasis and PsA. METHODS: A retrospective cohort study using Korean health insurance data (January 2008-October 2021) included patients diagnosed with psoriasis or PsA treated with biologics, nonbiologic systemic therapy, or phototherapy. The primary outcome was MACE (acute myocardial infarction, stroke, cardiac arrest, unstable angina, or heart failure). Multivariable time-dependent Cox regression models were used for risk analysis. RESULTS: The study included 183,212 patients, yielding 259,475 treatment episodes. Biologic therapy was associated with a lower risk of new-onset and recurrent MACEs compared to phototherapy (adjusted hazard ratio, 0.454; 95% confidence interval [CI], 0.359-0.574; 0.343, 95% CI, 0.245-0.479, respectively). Nonbiologic systemic therapy showed a lower MACE risk than did phototherapy only in patients with a history of MACE (adjusted hazard ratio, 0.789; 95% CI, 0.658-0.946). LIMITATIONS: Observational design limits causal inference and may involve residual confounding. CONCLUSION: The study supports the use of biologics in patients with moderate-to-severe psoriasis or PsA, particularly those with a MACE history where treatment options are limited.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Song WJ, Oh S, Yoon HS, et al. Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study. J Am Acad Dermatol. 2025. PMID: 40154667. doi:10.1016/j.jaad.2025.03.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。